Publication - 2017A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo

Publication

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo

Simvastatin inhibits interferon-γ signaling by blocking activation of STAT and prevented and reversed disease in our mouse model. We conducted a small, randomized, double-blind, placebo-controlled, phase II clinical trial to test simvastatin as a treatment for vitiligo. Our study does not support the use of oral simvastatin for the treatment of vitiligo. Disparate findings in this study compared with our mouse model may be a result of dosing limitations in human beings because of potential toxicity, which is not a concern in mice.

Full text   

Vanderweil SG, Amano S, Ko WC, Richmond JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B, Harris JE



FAQOther Questions

  • Is vitiligo contagious?

    Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo i...

  • Do Antioxidant Supplements Help Vitiligo?

    Do Antioxidant Supplements Help Vitiligo? Short answer Maybe a little. But probably not in the way most people hope. Antioxidant supplements may offer modest support, especially...

  • Vitiligo trials for kids: basics for the parents

    Pediatric vitiligo trials · The basics Two parallel studies are evaluating investigational use of ruxolitinib cream in young children — researchers are still finding out how wel...